Plain-English translation of NCT05518903 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new diagnostic imaging scan called 68Ga-FAPI-46 PET to help doctors see cancer-associated fibroblasts — special cells that grow around pancreatic tumors. The scan uses a small amount of radioactive material to highlight these cells and help doctors understand if surgery would be beneficial for patients with early-stage pancreatic cancer.
Current imaging methods sometimes cannot accurately predict whether surgery will help pancreatic cancer patients or if the cancer is too advanced. This medication and scan could help doctors make better treatment decisions by showing the extent of cancer-related cell growth more clearly.
You likely qualify if…
You likely don't qualify if…
You would receive the imaging medication by IV injection and wait about an hour for it to circulate in your body. Then you would have a PET/CT scan, which takes about 30 minutes. You would have scans at your baseline visit before starting treatment, possibly two more scans about 8 weeks apart during regular check-ups, and one more scan within 4 weeks after surgery (if you have it). The study includes follow-up visits for 5 years to track your health outcomes.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States